Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30702030 | 1.00 | P2RX3 (0.31) | P2RX3GRM4ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL27192020 | 0.93 | P2RX7 (0.34) | P2RX3GRM4ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30701988 | 0.91 | MAPT (0.32) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL27191996 | 0.91 | MAPT (0.32) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL30702077 | 0.91 | CYP1A2 (0.32) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL27191908 | 0.91 | CYP1A2 (0.32) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL27192044 | 0.89 | CYP3A4 (0.32) | P2RX3GRM4ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30702000 | 0.88 | LMNA (0.33) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL27192054 | 0.88 | LMNA (0.33) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL27192025 | 0.88 | CYP1A2 (0.32) | P2RX3ALDH1A1CYP1A2CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | P2RX3 4454/4885GRM4 4315/4885ALDH1A1 3259/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | P2RX3 4454/4885GRM4 4315/4885ALDH1A1 3259/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | P2RX3 4454/4885GRM4 4315/4885ALDH1A1 3259/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | P2RX3 4454/4885GRM4 4315/4885ALDH1A1 3259/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | P2RX3 4454/4885GRM4 4315/4885ALDH1A1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.